Saqib Islam, who had been leading Alexion Pharmaceuticals’s (NASDAQ: [[ticker:ALXN]]) business development efforts, has been hired by Cambridge, MA-based Moderna Therapeutics. He’ll reprise a similar role at Moderna, where he’ll begin serving as the company’s chief business officer effective May 9. Moderna and Alexion are already quite familiar with one another. The two inked a partnership in early 2014, and Alexion made an equity investment in Moderna as part of the deal.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler